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Modelling ligand selectivity of serine proteases
using integrative proteochemometric approaches
improves model performance and allows the
multi-target dependent interpretation of features†
Qurrat U. Ain,a Oscar Me´ndez-Lucio,a Isidro Corte´s Ciriano,b The´re`se Malliavin,b
Gerard J. P. van Westenc and Andreas Bender*a
Serine proteases, implicated in important physiological functions, have a high intra-family similarity,
which leads to unwanted oﬀ-target eﬀects of inhibitors with insuﬃcient selectivity. However, the
availability of sequence and structure data has now made it possible to develop approaches to design
pharmacological agents that can discriminate successfully between their related binding sites. In this
study, we have quantified the relationship between 12625 distinct protease inhibitors and their
bioactivity against 67 targets of the serine protease family (20 213 data points) in an integrative manner,
using proteochemometric modelling (PCM). The benchmarking of 21 diﬀerent target descriptors
motivated the usage of specific binding pocket amino acid descriptors, which helped in the identification
of active site residues and selective compound chemotypes aﬀecting compound aﬃnity and selectivity.
PCM models performed better than alternative approaches (models trained using exclusively compound
descriptors on all available data, QSAR) employed for comparison with R2/RMSE values of 0.64  0.23/
0.66  0.20 vs. 0.35  0.27/1.05  0.27 log units, respectively. Moreover, the interpretation of the PCM
model singled out various chemical substructures responsible for bioactivity and selectivity towards
particular proteases (thrombin, trypsin and coagulation factor 10) in agreement with the literature. For
instance, absence of a tertiary sulphonamide was identified to be responsible for decreased selective
activity (by on average 0.27  0.65 pChEMBL units) on FA10. Among the binding pocket residues, the
amino acids (arginine, leucine and tyrosine) at positions 35, 39, 60, 93, 140 and 207 were observed as key
contributing residues for selective aﬃnity on these three targets.
Background
While the human genome encodes more than 3000 potential
drug targets,1 only B800 of them have been successfully
exploited pharmacologically due to a number of limitations
(for instance, less compounds satisfying the Lipinski’s rule-of-
five or the redundancy of targets due to orthologs).2,3 The
traditional drug discovery process includes target identification
and validation. Subsequent screening campaigns identify hit
compounds, which can be optimized to leads and progress into
clinical trials.4 In silico approaches have been proven to be
successful in many phases of this process.5,6
It has been recently demonstrated that drugs exert their
therapeutic eﬀect by modulating more than one target,7 extend-
ing the notion of the one drug one target premise.8 While drug
discovery eﬀorts have been long focussed on single target
potency optimization,9 the rapid growth of bioactivity data-
bases sparks novel methods to use the data for addressing
ligand selectivity and polypharmacology.10–12
Quantitative Structure Activity Relationship (QSAR) model-
ling relates compound activity on a target to compound pro-
perties through machine learning models. However, a single
QSAR cannot predict drug potency and selectivity against a
panel of targets.13 Current chemogenomic approaches relate
biomolecular targets and their ligands on the basis of molec-
ular similarity, where ‘similar ligands show similar activity’ and
‘similar proteins bind similar ligands’.14 Although these tech-
niques enable the extrapolation on either the biological or the
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chemical side, it is not possible to fully extrapolate the bio-
activity of novel compounds on novel targets. Proteochemometric
modelling (PCM) integrates compound and target information
simultaneously in a single machine learning models. This combi-
nation of diﬀerent, yet complementary, sources of information
sets PCM apart from QSAR and chemogenomics, and permits to
both inter- and extrapolates the bioactivity of (novel) compounds
to (novel) targets.
Technically, the diﬀerence between PCM and QSAR is the
addition of explicit target descriptors. Thus, each ligand–target
interaction is numerically encoded by the concatenation of
ligand and target descriptors. Encoding protein information
into numerical descriptors is an intricate task.15–17 The most
common approaches consist of concatenating amino acid
descriptors,15–19 which can correspond to the residues in a
binding site or describing the full protein sequence with e.g. the
frequency of amino acid pairs, or of exploiting 3-dimensional
information when available20–22 (e.g. by using physicochemical
properties of protein cavities).
PCM has been applied to a number of target families
including glucocorticoid receptors,23 amine G-protein coupled
receptors (GPCR),24–26 melanocortin receptors,27 a wide range
of kinases,18,28–32 HIV protease and dengue virus NS3 pro-
teases.33–37 These models successfully identified the discrimi-
nating residues for DNA binding,23 mutations contributing to
HIV resistance38 and a correlation between the peptide sub-
strate and the protease kinetics.39 For further information the
reader is referred to three recent PCM reviews.22,40,41 To date,
PCM has been applied on various enzyme families including
trypsin-like serine proteases and other members of the protease
family (aspartic, cysteine and metallo proteases).42,43 In this
study we focused exclusively on serine proteases and addressed
their selectivity towards inhibitors.
Here, our main focus is to model the inhibition of serine
proteases by small molecules. Firstly, we generate a PCM model
to predict the aﬃnity of small molecules for the serine protease
family. Secondly, we benchmark 21 protein descriptors, compris-
ing both whole sequence and amino acid descriptors. Finally, we
also aim to identify the structural features of both compounds
and targets aﬀecting compound aﬃnity toward thrombin
(THRB), trypsin (TRY) and coagulation factor 10 (FA10).
Materials and methods
Dataset
The dataset used to generate the models comprised 12 625
distinct inhibitors (20213 data points) assayed against 67 protein
targets (20213 datapoints, matrixB30% complete). The complete
dataset was obtained from the ‘Directory of Useful Decoys-
Enhanced’ (DUD-E),44 Binding Database (Binding DB),45 ZINC46
and ChEMBL-17 databases (10.6019/CHEMBL.database.17).10,47–49
The number of known compound activities per target is given in
ST1 (ESI†) along with their UniProt and PDB IDs.50 pChEMBL
(log 10(activity (nM))) values of five types of activity values
were used (IC50, Ki, AC50, EC50 and Kd). The pChEMBL value
(Fig. SF1, ESI†) ranges from 3.4 to 11.7. According to this
distribution, the dataset contains 15 375 active datapoints
and 4821 inactive datapoints.
Assay identity descriptor (AID)
Publicly available IC50, AC50 and EC50 types are heterogeneous
and assay specific.12,51 Thus, in order to combine datapoints
with diﬀerent bioactivity values, we added a binary identifier to
the compound and target descriptors, which specifies the
activity type (IC50, Ki, AC50, EC50 or Kd) corresponding to each
datapoint. We term these descriptors as assay identity descrip-
tors (AID). Formally, AID is defined as:
AID(i, j) = d(i  j)(i A 1,!, Ndatapoints, j A 1,!, NAT)
where d is the Kronecker delta function, Ndatapoints is the total
number of datapoints and NAT is the number of distinct activity
types. It is a pure identifier containing no other information
but the standard type of bioactivity value. These types of
descriptors help to improve the additive predictive capability
of the model through inductive transfer of knowledge (IT)
between datapoints as explained by Brown et al.17
Chemical descriptors
Molecules were standardized by applying the following filters:
‘‘Remove Fragments’’, ‘‘Neutralize’’, ‘‘Remove explicit hydro-
gens’’, ‘‘Clean 2D’’, ‘‘Clean 3D’’ and ‘‘Tautomerize’’ using
JChem standardizer, JChem 6.3.1, 2013, ChemAxon (http://
www.chemaxon.com). Subsequently, 188 MOE physicochemical
descriptors and 256 bit circular fingerprints (radius = 2) were
calculated using MOE 2012.1052 and RDKit (http://www.rdkit.org)
respectively.53
Protein descriptors
Sequences were aligned using the Blosum62matrix in Clustalw,54,55
whereas the superimposition and structural alignment of drug
targets was performed using Chimera 1.6.56 Binding site residues
were selected on the basis of a 3D structural alignment of the
targets. As structural information was not available for some of the
proteins, sequence alignment of the cavities in homologous pro-
teins was used instead. Six amino acid (alignment dependent)
descriptors, namely Z-scales, FASGAI, MS-WHIM, protein features,
ST scales and T scales15,16 were calculated for the aligned binding
site residues with the function AA_descs of the R package camb.57
Descriptor values for sequence alignment gaps were set to zero. The
following full protein sequence descriptors (alignment independent
descriptors) were calculated using Protpy:19 amino acid composi-
tion (AAC), dipeptide composition (DPC), autocorrelation para-
meters, Moran autocorrelation (MA), normalised Moreau–Broto
autocorrelation (MBA), sequence order coupling number (SOCN),
Geary autocorrelation (GA), quasi sequence order (QSO) and com-
position, transition and distribution (CTD) descriptors. Addition-
ally, the Profeat58 descriptor, which is a combination of all full
protein sequence descriptors mentioned above, was computed.
In order to investigate the predictive power of 3D target
information,59 the volume of the binding pocket of each target
was calculated using trj_cavity.60 Trj_cavity is a protein cavity
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analysis software, designed to characterise the cavities present
in protein structures extracted from molecular dynamic (MD)
trajectories. By using an optimised MD protocol, it identifies
the binding pocket, whose coordinates are given by the user,
and calculates the static cavity volume. The cavity volume was
employed as a baseline to compare the predictive signal align-
ment dependent and independent descriptors.
Model training
Data pre-processing. The complete data matrix was indexed
by datapoints and columns by compound and target descrip-
tors. Datapoints were centred to zero mean and scaled to unit
variance, followed by removal of columns for which variance
was near to zero with the function nearZeroVar from the R
package camb57 (frequency cut-oﬀ = 30/1). Model training was
performed using random forest (RF) and were built with the R
package caret.61
Parameter optimization
In order to reduce the dimensionality of the input space, the
recursive feature elimination (RFE) method was applied on
both compound and target descriptors.62,63 Random forest
models were tuned using number of trees (ntree) equal to 500
and the default number of variables at each layer (mtry =
number of variables/3 in case of regression). Model training
was performed using the train function of the R package caret.61
Model validation
The partitioning of the data set into a training (70% of the data)
and a test set (30% of the data) was performed using the
createDataPartition function of the R package caret.64 Nested
cross-validation and grid search was used for parameter opti-
misation by dividing the training set into five folds (k = 5). A
model was trained on k  1 folds, which was used to predict the
bioactivities of the remaining fold. This procedure was repeated
k times for each combination of parameter values. The combi-
nation of parameter values displaying the lowest average root
mean square error (RMSE) value along the k folds was con-
sidered as optimal. Then, a model was built on the whole
training set using these values for the parameters.
In order to evaluate the extrapolation capabilities of the
model to novel serine proteases, we employed leave-one-target-
out (LOTO) validation. In LOTO, all datapoints corresponding
to a given target/protein were held out of the training set.
Subsequently, a model was trained on the remaining data,
and the bioactivities for the hold out set were predicted. This
type of analysis helped in assessing how well a PCM model
predicts the bioactivities for a set of compounds on a target for
which no information was presented to the model during the
training phase.65–67
In order to determine the predictive power of the models on
the test set, two metrics were used: R2 (coeﬃcient of determina-
tion) and the root mean square error (RMSE) of prediction
(explained in the ESI†).68 A model is considered as predictive if
the R2 value on test set is higher than 0.6 and the RMSE less
than 1 log units.68
Applicability domain
The applicability domain (AD) of a model is defined as the
extent of chemical space, and target in PCM, to which a model
can be reliably applied.69 There are various approaches to
determine the AD and these highlight the limitations of the
model. For example, k-nearest neighbours, probability density
distribution, bounding box, distance measures and kernel
methods such as Gaussian processes.70–75 Here we used the k
nearest neighbours algorithm to determine the AD of the PCM
models in the following way. The distance of each compound to
its five nearest neighbours in the training set was calculated.
Then, the mean similarity of that compound to its neighbours
was plotted against the compound’s absolute error in predic-
tion, which is defined as the absolute value of the difference
between the predicted and the observed bioactivities. Here, the
aim is to look for a similarity threshold above which our PCM
model can reliably predict the activity of new compounds. To
do that, a criterion was set for our PCM model, which states
that a PCM model is considered to be predictive if it has a
correlation of 0.6 or above and an RMSE less than 1 log units.
Feature analysis
Each bit in the compound descriptors encodes the presence
or absence of a chemical substructure, whereas the values of
the Z-scales account for physicochemical properties of the
amino acids. The influence of each compound substructure
and amino acid property on bioactivity was evaluated in the
following way. The value of the descriptor was set to zero in all
compound or amino acid descriptors presenting it. Then, a
PCM model was used to predict the bioactivity of compounds
using the updated descriptors.
This procedure was repeated for all compound and amino acid
descriptors. The analysis was calculated on the basis of the final
PCM model trained on all bioactivities, however, due to a lack of
data in the training set, chance correlations could happen in the
case of certain features of compounds. Here, the threshold (esti-
mated number of datapoints per target) required for a model to
reliably predict the feature analysis was not analysed as it is out of
the scope of the current study. Instead the average eﬀect of a
feature was calculated as the diﬀerence in the predicted activity of a
compound with and without a given compound substructure or
amino acid Z-scale, indicating whether its average influence is
beneficial or deleterious on bioactivity as was done previously.67,76
A cut-oﬀ value of0.2 pChEMBL units equal to themean of activity
diﬀerence distribution was established to discriminate which
compound substructures or amino acid properties influence the
bioactivity (Fig. SF4, ESI†). This analysis was only conducted on
THRB, FA10 and TRY, due to the high number of datapoints
annotated on these targets, which guarantees statistical robustness.
Results and discussion
Characterization of the biological space
In order to characterise the biological space, we measured the
average sequence similarity between all 67 targets using binding
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site amino acid descriptors. The similarity ranged from 43% to
58%. Table ST2 (ESI†) contains all binding site amino acids
considered. The clustering of similar targets in the heat map
(Fig. 1A) using binding site residues can also be observed in the
clusters of the phylogram (Fig. 1B). In total, we observed 11 big
clusters, corresponding to the following sub-families: thrombin
(THRB), coagulation factor (FA10), trypsin (TRY), plasminogen
(PLMN), cathepsin-G (CATG), chymotrypsin (CTR a/b), tryptase
(TRYB), elastase (CEL), urokinase (UROK), transmembrane pro-
tease serine (TMPS) and kallikrein (KLK). Homologs of each
subfamily were clustered together in the tree, however a few
exceptions were observed for members of the following families:
FA12, FA11, FA7, serine protease hepsin (HEPS), prostasin
(PRSS8) and TMPS2. The targets THRB, TRY and FA10 clustered
together suggesting that they are similar enough to enable PCM
to inter- and extrapolate compound bioactivity among them.
However, there are binding site variations, which might be
responsible for the increase or decrease of compound binding
aﬃnity across these three proteases.
The combined chemical and biological space, termed here
as compound–target interaction space, was visualized using
both compound and target descriptors. A PCA analysis (Fig. 2)
showed that each compound–target group is separated from
the others due to B41% sequence divergence and the struc-
tural diversity of the compounds. However, the three biggest
clusters of compound–target pairs in the figure (green: FA10,
purple: THRB, pink: TRY) lie close to each other in PCA space
enabling the discovery of selective features of these targets. The
rest of the targets were found as an overlapping cluster on the
top left corner of the PCA plot, explaining the widened chemical
Fig. 1 Serine protease binding site. (A) Similarity heat map of the 67 serine proteases considered in this study, calculated with 3 Z-scales. The distance
between clusters of each target is also reflected in the tree. (B) The distance matrix between 67 drug targets was calculated using tanimoto similarity
between protein descriptors and plotted in the form of a phylogram. Each cluster is represented by a sub-family name and contains the homologs of the
family. Few exceptions can be seen in the case of FA12, FA11, FA7, HEPS, PRSS8 and TMPS2, which are clustering with diﬀerent subfamilies than their own.
The targets having 3D information stored in PDB are underlined by a red line.
Fig. 2 Chemical and biological space (compound–target interaction
space) of protease inhibitor dataset. The PCA analysis of chemical descrip-
tors and amino acid descriptors shows an overlap of compound properties
per target in PC1 and PC2 space. PC1 (34% variance) shows that the target
descriptors influence the spread of data points, clustering the compounds
belonging to FA10 and TRY closer to each other, with THRB forming an
outer cluster (also shown in phylogram Fig. 1B). PC2 explains the distinct
clusters of seven different species (represented with different shapes) used
in the study. The dataset has maximum information of human targets,
however, the additional orthologous information is distinctly visible using
binding pocket features.
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and biological space by addition of combined bioactivity data.
When the loadings of each principal component were investi-
gated, it was found that maximum variance was explained by
the binding pocket sequence descriptors in the biological
space. PC1 is loaded mainly by first and second principal
components of the Z-scales (34% variance), which summarises
the lipophilicity (Z1) and steric bulk properties (Z2) of amino
acids, whereas, PC2 (26% variance) is more related to Z-3 of the
most varied amino acids in the pocket sequence (e.g. position
56, 140, 177 and 231), explaining the properties like electro-
philicity and electronegativity of amino acids.77 PCA also
showed that the orthologs are within the targets space defined
by FA10, THRB, and TRY. Hence we expected to be able to
include them in our data set.
PCM model
Protein descriptor selection. Almost all protein descriptors
met our criterion for a predictive model (mentioned in materials
section) and allowed the generation of models with high pre-
dictive power (mean Rtest
2 = 0.72  0.06, mean RMSEtest = 0.77 
0.09 log units) (Table 1). Models trained on alignment depen-
dent descriptors, i.e. binding pocket amino acid descriptors,
displayed mean Rtest
2 and RMSEtest values of 0.67  0.05 and
0.83  0.07 pChEMBL units, respectively (Table 1). From these
the PCM model built (Table 2) on circular fingerprints and
binding site descriptors, 3 Z-scales was found to be the most
predictive (RCV
2 = 0.946, RMSECV = 0.34 log units; Rtest
2 = 0.78,
RMSEtest = 0.70 pChEMBL units), and was thus used for the
interpretation of the structural features of both compounds and
targets implicated in binding aﬃnity and selectivity (Model
interpretation section). Despite the presence of gaps in the
binding pocket sequence alignment, we obtained high perfor-
mance when using binding site amino acid descriptors. Here
Z-scales (3) were selected in spite of better performance of
Z-scales (5) (RMSEtest = 0.69 vs. 0.70 pChEMBL units) because
of a number of arguments. Firstly, Z-3 (162 bit vector) utilizes
less variable space than Z-5 (270 bit vector). Secondly, the 3
primary Z-scales were derived from the properties of natural
amino acids, whereas, Z-4 and Z-5 resulted in an extended PLS
analysis required to expand the original dataset to 87 amino
acids (including non-natural). The 4th and 5th are hence more
diﬃcult to interpret moreover they have been found to add little
to performance in previous PCM models.15,77 Although there is
room for improvement in binding site definitions for protease
targets, e.g. by refining the description of the binding sites, these
data indicate that the explicit introduction of binding site
residue descriptors provide a signal on par with full sequence
descriptors but provide better interpretability.
Although, the predictive power of MBA and SOCN full
sequence descriptors (Table 1) was comparable with binding
pocket descriptors (mean Rtest
2 = 0.78  0.01, mean RMSEtest =
0.68  0.03 log units) (Fig. 3), full sequence descriptors do not
permit a biologically meaningful interpretation of the models;
hence, 3 Z-scales were used for generation of the final
PCM model.
Simple descriptors. Next, we evaluated whether 1D binding
site (cavity) and amino acid physiochemical property descrip-
tors were suﬃcient to generate predictive PCM models. We
observed a better model performance when using only simple
cavity descriptors such as binding site volume, AAC and DPC
compared to models trained on Prot_FP, VHSE, MSWHIM,
T-scales and ST-scales (Table 1). The binding site volume,
although expected to convey little target information,60 led to
satisfactory models according to our model validation criteria
(see section Model validation), namely: R2 = 0.74 and RMSE =
0.74 pChEMBL units. These results are in agreement with the
study of Bender et al.,78 where the authors reported that 1D
molecular descriptors (e.g. molecular weight or atom counts)
play a significant role in enhancing the enrichment of active
compounds in virtual screening.
The high performance of models trained on binding site
volume indicates that descriptors accounting for structural
information of the binding site lead to models displaying slightly
worse performance than those trained on more sophisticated
Table 1 Performance analysis of the protein descriptors used in the PCM
model. The complete dataset containing 20213 data points on 67 protease
targets were employed in a PCM model using structural fingerprints and
protein descriptors. All protein descriptors showed an approximately
similar performance. However, the Z-scales combined good performance
and interpretability and were used in the final model. The feature type of
each descriptor is added for clarity to the reader, FSD indicates the ‘‘Full
Sequence Descriptor’’ whereas BSD indicates ‘‘Binding Site Descriptor’’
Features
Feature
type Rtest
2 RMSEtest
Moran autocorrelation (MA) FSD 0.78 0.66
Moreau–Broto autocorrelation (MBA) FSD 0.78 0.67
Z-scales (3) BSD 0.78 0.70
Quasi-sequence order (QSO) FSD 0.78 0.68
Geary autocorrelation (GA) FSD 0.78 0.68
Z-scales (5) BSD 0.78 0.69
Sequence order coupling numbers (SOCN) FSD 0.78 0.71
Composition, transition and distribution (CTD) FSD 0.77 0.70
ProFeat FSD 0.77 0.70
Amino acid composition (AAC) FSD 0.75 0.74
Dipeptide composition (DPC) FSD 0.74 0.73
Volume BSD 0.74 0.74
ProtFP PCA (3) BSD 0.68 0.83
ST-scales BSD 0.66 0.86
VHSE BSD 0.66 0.86
ProtFP PCA (8) BSD 0.65 0.86
FASGAI BSD 0.64 0.87
T-scales BSD 0.64 0.87
ProtFP PCA (5) BSD 0.63 0.88
ProtFP (feature) BSD 0.63 0.91
MSWHIM BSD 0.61 0.91
Table 2 Model performance. Correlation coeﬃcients and RMSE values
on the test set for PCM and QSAR models with diﬀerent combination of
descriptors. PCM models outperformed global and individual QSAR
models
Methods Descriptors Rtest
2 RMSEtest
QSAR (validated per target) Circular FP 0.35  0.27a 1.05  0.27a
QSAR (global) Circular FP 0.38 1.09
PCM (validated per target) Circular FP, Z3 0.64  0.23a 0.66  0.20a
PCM (global) Circular FP, Z3 0.78 0.70
a Mean value of correlation coeﬃcient and predicted errors (RMSE).
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protein information as described above. Thus, we anticipate that
using more complex structural cavity descriptors alone, or in
combination with amino acid or full protein sequence descrip-
tors, is likely to increase model performance.
Comparison of PCM with QSAR
In order to assess whether the inclusion of explicit protein
information improves model performance, we trained models
on exclusively compound descriptors using the datapoints
annotated on a given target (individual QSAR models), or all
available datapoints, termed as global or Family QSAR
(Table 2).17 The global QSAR model exhibited significantly
worse performance than PCM (RMSEQSAR = 1.09, RMSEPCM =
0.70 pChEMBL units). Similarly, PCM also outperformed per
target QSAR models, with mean RMSEQSAR and RMSEPCM
values on the test set of 1.05  0.27, and 0.66  0.20 pChEMBL
units, respectively. This indicates that the explicit inclusion of
target information in PCM improves the prediction of bioactivities
of the compounds on this dataset.
Leave one target out (LOTO) validation
Subsequently, the 67 proteases were grouped into 11 sub-
families according to their similarity, which was calculated on
binding site amino acid descriptors (Fig. 1B). These groups
contained both orthologs and paralogs when applicable. Fig. 4
and Table 3 report the sub-family averaged leave one target out
(LOTO) performance. Additionally, the individual performance
of LOTO validation on each target is shown in ST3 in the ESI.†
LOTO validation was performed to assess the extrapolation
ability of PCM on the target space. We obtained a mean
predictive performance (R2) of 0.42  0.15 for all 67 targets
with a prediction error (RMSE) of 1.03  0.22 pChEMBL units.
LOTO models for CTRL, FA10, TMPS and THRB displayed poor
performance with mean R2/RMSE values of (0.35  0.07/1.37 
0.57, 0.35  0.22/1.33  0.55, 0.33  0.29/1.29  0.64 and
Fig. 3 Benchmarking of 21 protein descriptors. (A) Correlation coeﬃcient
(R2) and RMSE values on the test set calculated using the model trained on
11 alignment dependent binding pocket descriptors. (B) Performance
analysis of 10 alignment independent descriptors applied on full protein
sequences. The figure provides an overview of all descriptors employed.
The final model, generated using 3 Z-scales as protein descriptors,
displayed the highest predictive power of the binding site based descrip-
tors (R2 = 0.78, RMSE = 0.70).
Fig. 4 Leave one target out (LOTO) validation. The average LOTO per-
formance was R2 = 0.43  0.15. The worst modelled targets are CTRL
(R2/RMSE = 0.35  0.07/1.37  0.57), FA10 (R2/RMSE = 0.35  0.22/1.33 
0.55), TMPS (R2/RMSE = 0.33  0.29/1.29  0.64) and THRB (R2/RMSE =
0.46  0.37/1.20  0.45). The performance for the rest is comparable.
The predictions performed on each target as a test set yielded an error of
B1 log units, showing the ineﬃciency of predictions by the model in the
case of complete absence of target information from the training set.
Table 3 Predictive performance and mean square error of leave one
target out (LOTO) validation. LOTO was performed on all 67 targets and
then categorised together into 11 diﬀerent sub-families
Target sub family Mean Rtest
2
Mean RMSEtest
(log units)
CTRL 0.35  0.07 1.37  0.57
FA10 0.35  0.22 1.33  0.55
TMPS 0.33  0.29 1.29  0.64
THRB 0.46  0.37 1.20  0.45
TRYB 0.20  0.09 1.09  0.19
CELA 0.42  0.43 1.06  0.33
CATG 0.36  0.37 0.94  0.31
UROK 0.77  0.38 0.92  0.41
TRY 0.46  0.17 0.90  0.29
KLK 0.40  0.32 0.78  0.52
PLMN 0.60  0.29 0.64  0.28
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0.46  0.37/1.20  0.45 respectively). This decrease in perfor-
mance was expected, as 35% of the datapoints in the dataset
are annotated on FA10 and THRB. Hence, removing either of
them removes a large fraction of the compound–target inter-
action space and thus deteriorates model performance. On the
other extreme, TMPS and CTRL are annotated with 0.85% of
the datapoints and present an average similarity to the other
targets considered of B43% (Fig. 1B), which is plausibly the
reason for the poor performance of their corresponding LOTO
models. The low performance of the LOTO model for the CTRL
subfamily, with an RMSE equal to 1.37 0.57, likely arises from
the low similarity of the members of this family with respect to
the other proteases considered here. This can be seen in
Fig. 1A, where the CATG subfamily clusters along with HEPS,
KLKB1 and other diverse member of TMPS. Taken together,
these data indicate that the performance of LOTO models is
correlated to the presence of similar proteases in the training
set and wherever a diverse protein target is present with less
information, the predictability of PCM models decreases with
an increase in prediction error.
Although all targets show a close resemblance of the binding
pocket in the structural alignment (Table ST1, ESI†), there is
considerable variation at several positions, namely: 35, 37, 40,
60, 96, 97, 124, 148, 174, 175, 205, 206, 207, 209, 222, and 227.
Out of these variations, amino acids at the 35, 39, 60, 93, 140,
and 207 positions were found to aﬀect the binding aﬃnity
(Model interpretation section). Given the lower similarity
between the targets in the training set (average sequence
similarity = B41%) as compared to previous studies where
the similarity threshold was above 90%,34,79 both the inter-
polation and extrapolation power of PCM on this data set are
notable. Thus, PCM appears as a suitable approach to model
compound bioactivities on the serine protease family.
Overall, these data suggest that our PCM models display fair
extrapolation performance for proteases similar to those pre-
sent in the training set.
Applicability domain
The results from our applicability domain analysis are shown in
Fig. 5, which reports the compound similarity averaged over the
5 nearest neighbours against the RMSE values for the com-
pounds in the test set. We obtained high RMSE values, up to
3 pChEMBL units, for compounds displaying a neighbour-
averaged similarity value below 0.92. RMSE values gradually
decrease, to a minimum value of 0.02 pChEMBL units, as the
compound neighbour-averaged similarity increases. In prac-
tice, a new compound exhibiting a neighbour-averaged simi-
larity value equal to or greater than 0.90 is likely to be predicted
with good accuracy. Nevertheless, we observed some outliers. For
instance, two compounds (CHEMBL345710, CHEMBL109601)
having a similarity value of B0.94 were found to have an
exceptionally high prediction error, namely 3.21 and 3.11
pChEMBL units on FA10 and CATG targets. One of these
compounds (CHEMBL345710) displays pChEMBL values of
4.20, 4.67 and 6.07 towards FA10, THRB and TRY, whereas the
other compound (CHEMBL109601) exhibits bioactivity values of
4.08, 6.27, 8.07 and 6.36 pChEMBL units towards CATG, TRY, CEL
and CMA. Together, these observations indicate that our models
could not predict the selectivity of these two compounds towards
FA10 and CATG, as the bioactivities of their closest neighbours are
considerably higher, namely more than 2 pChEMBL units.
In conclusion, these data indicate that estimating the error
for individual predictions constitutes a valuable source of
information in PCM-guided drug discovery campaigns.80
We also performed an applicability domain analysis on the
target space. However, we did not observe a correlation between
target similarity and error in prediction, likely due to the fact
that most of the proteases are similar to each other (average
sequence similarity = 46%; Fig. SF2, ESI†). However, the addi-
tion of diverse target space (protein sequences of KLK, TMPS,
HEPS) is also one of the limitations of poor predictability of the
model. There were not enough datapoints available against
these targets in the training set; also the compound space was
equally sparse, which resulted in poor prediction performance.
Chemical interpretation of the models
This analysis was performed on three targets, namely THRB,
TRY and FA10. Fig. 6 reports the influence of compound
substructures and binding site amino acid properties on bioac-
tivity. A tertiary sulphonamide (Fig. 6 substructure: a0) was
singled out to be important for selectivity against FA10.
Absence of this substructure decreased the predicted activity
of the compound on average by 0.27  0.65 pChEMBL units
against FA10, whereas it increased the bioactivity against THRB
and TRY by on average 0.36  0.60 and 0.55  0.73 pChEMBL
units, respectively. Thus, the presence of tertiary sulphonamides
appears correlated to compound aﬃnity towards FA10 and
uncorrelated to aﬃnity on THRB and TRY. We validated this
prediction using the 3D crystallographic structures of FA10 and
THRB. These structures let us confirm that a tertiary sulphon-
amide is implicated in strong hydrogen bonds with the
Fig. 5 Measuring the reliability of the model using the applicability
domain. The figure visualises the absolute predicted error (y-axis) of test
compounds and the similarity to five nearest neighbours (x-axis) of these
test compounds in the training set. The predicted error decreases to a
minimum of 0.02 log units when the similarity of a new test compound
increases. The two outliers (CHEMBL345710, CHEMBL109601) are also
shown with a predicted error greater than 3 log units.
Integrative Biology Paper
O
pe
n 
A
cc
es
s A
rti
cl
e.
 P
ub
lis
he
d 
on
 1
6 
Se
pt
em
be
r 2
01
4.
 D
ow
nl
oa
de
d 
on
 2
8/
07
/2
01
5 
14
:5
0:
49
. 
 
Th
is 
ar
tic
le
 is
 li
ce
ns
ed
 u
nd
er
 a
 C
re
at
iv
e 
Co
m
m
on
s A
ttr
ib
ut
io
n 
3.
0 
U
np
or
te
d 
Li
ce
nc
e.
View Article Online
1030 | Integr. Biol., 2014, 6, 1023--1033 This journal is©The Royal Society of Chemistry 2014
backbone residue GLY-219 of FA10 (Fig. 7A). The other impor-
tant residues of the P1-motif of proteases,81 namely 99, 215 and
219 appear to be involved in ligand binding through van der
Waals and electrostatic interactions. However, no significant
interaction was observed between this compound substructure
and the binding pocket of THRB. This structural analysis
confirms the prediction that tertiary sulphonamides are speci-
fic for FA10 activity (Fig. 7A).
Similarly, absence of a primary sulphonamide (Fig. 6 sub-
structure: a) was observed to increase the predicted activity of
the compound on this target. Comparing the binding modes of
compounds containing tertiary sulphonamides (Fig. 6a0) and
primary sulphonamides (Fig. 6a) features led us to another
interesting investigation. The crystallographic structures of
both complexes were superimposed and showed that the bind-
ing mode of the ligands containing tertiary sulphonamides is
diﬀerent from that of ligands containing primary sulphon-
amide, and this diﬀerence leads to fewer interactions. This
structural analysis confirms the validity of the model inter-
pretation pipeline proposed here.
Furthermore, we identified that a secondary amide (Fig. 6b)
on average contributes to interactions (hydrogen bonding)
with the backbone residues SER-256 of the THRB receptor
(2BDY, 1EZQ, 1FXY). The feature analysis for this particular
compound substructure however suggested that its absence
could increase the predicted bioactivity of the compound on
these three targets.
Absence of methylamino-2-butenoic acid was predicted to be
beneficial for compound activity on average against FA10 but
detrimental against THRB and TRY (Fig. 6c). However, only one
compound in our dataset exhibited this feature, and we could
not find structural evidence in the literature for the interaction
of this feature with THRB, TRY or FA10. Thus, the paucity of
experimental data does not permit a complete interpretation of
the general influence of this feature on the inhibition of these
three proteases.
In addition to these features, we predicted that absence of a
prolinamide decreased the predicted bioactivity against THRB by
on average 0.10  0.66 pChEMBL units (Fig. 6d), whereas the
inverse picture was predicted for FA10 and TRY. When investigat-
ing the crystallographic structures available for THRB (PDB IDs:
1AE8 and 3RMM), we found that most of the THRB inhibitors
containing this feature interact with GLY-216 and GLY-219. How-
ever, no crystal evidence was found for TRY and FA10. Hence, we
anticipate that a prolinamide might be a selective feature for
THRB and is beneficial for activity against THRB.
Fig. 6 Contribution of compounds’ selective structural features towards the binding aﬃnity of three selected targets. Increase/decrease of predicted
binding aﬃnity of a compound by absence of a particular sub-structural fingerprint was mapped against FA10, THRB and TRY. A positive mean activity
diﬀerence means that absence of this feature is advantageous for activity, Whereas, a negative mean activity diﬀerence means that removal of a particular
feature is detrimental for activity. A cut-oﬀ of +0.2 and 0.2 log units was specified to select the features. Feature labelled as (a) represents primary
sulphonamide, whereas (a0) represents tertiary sulphonamide. Similarly (b), (c) and (d) represent secondary amide, methylamino-2-butenoic acid and
prolinamide respectively. The plot shows a combined selectivity and activity profile of compound features of three targets.
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Biological interpretation of the models
Next, we analysed the importance of binding site amino acid
properties on compound bioactivity (Fig. SF3, ESI†). Residues at
positions 35, 39, 60, 93, 140, and 207 were predicted to aﬀect
compound bioactivity on average by more than 0.2 pChEMBL
units. The presence of an arginine and leucine in THRB at
positions 35, 39 and 60 was predicted to be beneficial for
bioactivity. However, asparagine, phenylalanine and histidine
in FA10, and serine, phenylalanine and lysine in TRY at the
same positions, were predicted to decrease compound bio-
activity by on average 0.4  0.01 pChEMBL units. This eﬀect
illustrates the relevance of small and charged residues in the
binding site for compound bioactivity, in opposition to large
aromatic residues at positions 25, 39 and 60.
The absence of a positively charged arginine at position 93
was predicted to be less important for bioactivity in THRB than
a negatively charged glutamate in FA10. However, the absence
of any positively charged amino acids (arginine/lysine) in the
binding site of TRY leads to an average decrease in activity of
0.07  0.36 pChEMBL units. Furthermore, the presence of
lysine and tyrosine at positions 140 and 207, respectively, were
predicted to increase the bioactivity in FA10 by on average
0.07  1.06 and 0.05  1.06 pChEMBL units respectively.
However, as the impact of these residues on bioactivity towards
FA10, THRB and TRY is even less than the chosen cut-oﬀ
(0.2), no clear conclusion can be made. The positively charged
amino acid residues could favour compound–target inter-
actions and the presence of polar residues in the binding
pocket of FA10 could be beneficial for compound affinity,
however, stronger evidence in the form of interaction fingerprints
in addition to sequence descriptors may help to strengthen these
claims.
Conclusions
In the present study, we have introduced PCM for the predic-
tion of the potency of 12 625 distinct protease inhibitors on a
panel of 67 mammalian serine proteases. We have shown that
the inclusion of explicit target information improves the pre-
diction of compound bioactivity on serine proteases, as PCM
models outperformed both individual QSAR models and a
model trained on exclusively compound descriptors using all
datapoints (Family QSAR). We have benchmarked the predic-
tive power of a total of 21 protein descriptors, including
binding site amino acid and full protein sequence descriptors,
as well as 1D protein cavity descriptors, such as cavity volume,
and amino acid composition descriptors. We conclude that the
binding site amino acid and full protein sequence descriptors
provide comparable predictive signal. However, the usage of
binding site amino acid descriptors enabled a biologically
meaningful interpretation of the models in agreement with
the scientific literature.
Similarly, the description of compounds with keyed finger-
prints has permitted a chemically meaningful interpretation of
the PCM models. This analysis has singled out compound sub-
structures influencing compound potency and selectivity towards
particular proteases, such as primary and tertiary sulphonamides
for the selective inhibition of FA10, methylamino-2-butenoic acid
for the inhibition of THRB and TRY, and prolinamide for the
selective inhibition of THRB.
Overall, the proteochemometric approaches applied on this
dataset of serine proteases enabled us to interpret the target
information in a meaningful way, which also shows the benefits/
strength of incorporating protein-related information in compu-
tational chemogenomics.
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